Over the last decade, the treatment of advanced non-small cell lung cancer (NSCLC) has
undergone rapid changes with innovations in oncogene-directed therapy and immune …

Harnessing the broad immunostimulatory capabilities of chemotherapy in combination with
immune checkpoint inhibitors has improved immunotherapy outcomes in patients with …

Immunosuppression by the tumor microenvironment is a pivotal factor contributing to tumor
progression and immunotherapy resistance. Priming the tumor immune microenvironment …

Substantial improvement in prognosis among metastatic renal cell carcinoma (mRCC)
patients has been achieved, owing to the rapid development and utilization of …

Background There is still limited research on the association between immune cells and the
risk of prostate cancer. Further investigations are warranted to comprehend the intricate …

Among all malignant tumors, lung cancer has the highest mortality and morbidity rates. The
non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are the most …

Pancreatic cancer (PC) is a digestive malignancy with worse overall survival. Tumor immune
environment (TIME) alters the progression and proliferation of various solid tumors. Hence …

Autophagy is a highly conserved and natural degradation process that helps maintain cell
homeostasis through the elimination of old, worn, and defective cellular components …

DCs have great promise for cancer immunotherapy and are essential for coordinating
immune responses. In the battle against cancer, using DCs' ability to stimulate the immune …

The discovery of immune checkpoints and the development of immune checkpoint inhibitors
(ICI) have achieved a durable response in advanced-stage cancer patients. However, there …